PF-02341066
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for PF-02341066, covering 2011-10-18 to 2021-10-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer [Phase 1]